Dietary Capsaicin Reduces Obesity-induced Insulin Resistance and Hepatic Steatosis in Obese Mice Fed a High-fat Diet
Overview
Nutritional Sciences
Physiology
Affiliations
Obesity-induced inflammation contributes to the development of obesity-related metabolic disorders such as insulin resistance, type 2 diabetes, fatty liver disease, and cardiovascular disease. In this study, we investigated whether dietary capsaicin can reduce obesity-induced inflammation and metabolic disorders such as insulin resistance and hepatic steatosis. Male C57BL/6 obese mice fed a high-fat diet for 10 weeks received a supplement of 0.015% capsaicin for a further 10 weeks and were compared with unsupplemented controls. Glucose intolerance was estimated by glucose tolerance tests. Transcripts of adipocytokine genes and the corresponding proteins were measured by reverse transcription-PCR and enzyme-linked immunosorbent assay, and macrophage numbers were determined by flow cytometric analysis. Transient receptor potential vanilloid type-1 (TRPV-1), peroxisome proliferator-activated receptor (PPAR)-alpha, and PPARgamma coactivator-1alpha (PGC-1alpha) mRNAs were also measured by RT-PCR, and PPARalpha luciferase assays were performed. Dietary capsaicin lowered fasting glucose, insulin, leptin levels, and markedly reduced the impairment of glucose tolerance in obese mice. Levels of tumor necrosis factor-alpha (TNFalpha), monocyte chemoattractant protein-1 (MCP-1), and interleukin (IL)-6 mRNAs and proteins in adipose tissue and liver decreased markedly, as did macrophage infiltration, hepatic triglycerides, and TRPV-1 expression in adipose tissue. At the same time, the mRNA/protein of adiponectin in the adipose tissue and PPARalpha/PGC-1alpha mRNA in the liver increased. Moreover, luciferase assays revealed that capsaicin is capable of binding PPARalpha. Our data suggest that dietary capsaicin may reduce obesity-induced glucose intolerance by not only suppressing inflammatory responses but also enhancing fatty acid oxidation in adipose tissue and/or liver, both of which are important peripheral tissues affecting insulin resistance. The effects of capsaicin in adipose tissue and liver are related to its dual action on PPARalpha and TRPV-1 expression/activation.
Anyanwu G, Anzaku D, Bulus Y, Girgi J, Donwell C, Ihuma J J Obes. 2025; 2025:5568216.
PMID: 40026359 PMC: 11870763. DOI: 10.1155/jobe/5568216.
Wan X, Ma J, Bai H, Hu X, Ma Y, Zhao M Biomolecules. 2025; 15(1).
PMID: 39858534 PMC: 11764138. DOI: 10.3390/biom15010140.
Lee M, Doo M, Kim I, Kim Y Prev Nutr Food Sci. 2025; 29(4):422-429.
PMID: 39759824 PMC: 11699576. DOI: 10.3746/pnf.2024.29.4.422.
Maharjan A, Vasamsetti B, Park J Heliyon. 2024; 10(21):e39721.
PMID: 39524861 PMC: 11543913. DOI: 10.1016/j.heliyon.2024.e39721.
Novel derivatives of capsaicin as a potent hypolipidemic and anti-obesity agent.
Li F, Hou Y, Pang H, Song X, Li W Mol Divers. 2024; .
PMID: 39446255 DOI: 10.1007/s11030-024-10971-0.